Status and phase
Conditions
Treatments
About
A study to investigate the safety and reactogenicity of MT-5625 independently in adults aged 18-35 years, toddlers ages 12-24 months, and infants aged 6-10 weeks
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
ALL SUBJECTS
ADULTS ONLY
TODDLERS and INFANTS
TODDLERS ONLY
INFANTS ONLY
Primary purpose
Allocation
Interventional model
Masking
110 participants in 8 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal